Parabolic Drugs - News

NSE: PARABDRUGS | BSE: 533211

₹5.50

₹-0.25 (-4.35%)

As on 25-Jan-2021IST

Market cap

₹35 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

-0

Div. Yield

0 %

Annual Reports

Annual Reports

2018

Annual Reports

2017

Annual Reports

2016

Annual Reports

2015

Annual Reports

2014

Annual Reports

2013

Annual Reports

2012

Annual Reports

2011

Annual Reports

2010

Announcements

View Announcements

Recent

Important

Outcome Of Board Meeting Held On 11.02.2021 And Intimation Of Financial Results For The Quarter And Nine Months Ended 31.122020

11-Feb-2021

Corporate Insolvency Resolution Process (CIRP)-Public Announcement

08-Feb-2021

Board Meeting Intimation for Un-Audited Quarterly Financial Results For The Quarter And Nine Months Ended On 31St December 2020

05-Feb-2021

Fixation Of 'Record Date' For Suspension Of Trading Of Units/Scrip

25-Jan-2021

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

22-Jan-2021

Corporate Action-Intimation of Delisting

22-Jan-2021

Shareholding for the Period Ended December 31 2020

21-Jan-2021

Statement Of Investor Complaints For The Quarter Ended December 2020

21-Jan-2021

Corporate Action-Intimation of Delisting

19-Jan-2021

Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal

16-Jan-2021